Close Menu

private financing

Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.

Under the terms of the agreement, OpGen would sell $10 million in stock and warrants to a US-based healthcare-focused institutional investor.

The firm said the funding will support the launch of its miniaturized ELISA platform, which reduces the time and sample volume required for such assays.

Illumina Ventures led the round for the Santa Clara, California-based firm, which is developing applications for its optical detection technology.

The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.

The company said the funds would be used in part to expand its presence in the cell-analysis market in areas such as infectious disease.

The company has developed a platform, called e[datascientist], that uses artificial intelligence to analyze genomic and microbiomic data at scale.

Investors in the round included International Holdings Company (IHC), based in Abu Dhabi, United Arab Emirates, and RPMI Railpen, a UK pension fund.

The company said that it plans to use funds from its recent $18 million Series B round to drive instrument sales and develop AI tools for data analysis.

Investors included Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging technology.

Pages

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.